Bevacizumab + Capecitabine + Everolimus + Exemestane
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Breast Cancer Recurrent
Conditions
Breast Cancer Recurrent, HER2/Neu-negative Carcinoma of Breast, Hormone Receptor Positive Malignant Neoplasm of Breast
Trial Timeline
Aug 1, 2014 → Sep 30, 2017
NCT ID
NCT02248571About Bevacizumab + Capecitabine + Everolimus + Exemestane
Bevacizumab + Capecitabine + Everolimus + Exemestane is a approved stage product being developed by Novartis for Breast Cancer Recurrent. The current trial status is completed. This product is registered under clinical trial identifier NCT02248571. Target conditions include Breast Cancer Recurrent, HER2/Neu-negative Carcinoma of Breast, Hormone Receptor Positive Malignant Neoplasm of Breast.
What happened to similar drugs?
20 of 20 similar drugs in Breast Cancer Recurrent were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02248571 | Approved | Completed |
Competing Products
20 competing products in Breast Cancer Recurrent